Latest Safety News

Alterity Therapeutics has arranged an underwriting deal for up to 8.4 million ATHO options, potentially raising A$4.2 million to A$7.96 million ahead of their expiry. The funds aim to support the upcoming Phase 3 trial for ATH434 in Multiple System Atrophy and bolster working capital.

West Wits Mining has transitioned from developer to producer with first gold poured at Qala Shallows, backed by a $97 million project finance package and a resource base expanded to 7.24 million ounces.

Etherstack has agreed to an expanded scope on its key UK government project, adding £0.5 million (US$0.7 million) in revenue and lifting ongoing support fees, with positive impact expected in H1 FY27.

AML3D Limited surged to a record $12.5 million revenue in FY26, delivering its first half-year EBITDA profit and locking in a $29 million order book driven by US Defence contracts and UK market entry.

Avecho has resumed enrolment for the last stage of its pivotal Phase III trial of a TPM®-enhanced CBD capsule for insomnia, following a unanimous Data Monitoring Board recommendation to continue without expanding the sample size.

Verbrec Limited accelerated its growth trajectory in FY2026, driven by a strategic acquisition and divestment, delivering a 52% revenue increase and a near tripling of net profit.

X2M Connect Limited lifted revenue by 38% to $8.94 million in FY26, halving its net loss while laying groundwork for a new data centre business.

Kingsgate Consolidated delivered a record FY2026 net profit of $278 million, driven by strong gold and silver output at Chatree and a $68.6 million impairment reversal at the Nueva Esperanza project, while declaring a 10 cent final dividend.

xReality Group (ASX: XRG) delivered a standout FY26 with total income up 43% to $20 million and EBITDA surging to $3.8 million, backed by rapid expansion of its Operator XR defence training platform.

Alpha HPA Limited reported a 135% revenue increase but a 31% rise in net loss for FY2026, while progressing its Stage Two facility on schedule with robust customer demand exceeding 12,000 tonnes per annum under letters of intent.

EMVision has accelerated recruitment in its pivotal emu™ brain scanner trial, surpassing 200 patients and advancing FDA discussions to broaden clinical endpoints, setting the stage for regulatory submission in early 2027.

Ceretas Limited posted a $1.63 million net loss for FY26 on $1.28 million revenue from government grants, advancing its clinical-stage Alzheimer’s ultrasound platform. The company completed an $8 million IPO in July to fund pivotal trials and device development.